Traditional Core Values
Evolving Landscape
Fresh Approach
Turner Pope Investments is delighted to introduce a forthcoming AIM IPO
•TPI is sole bookrunner and broker
•An opportunity to invest alongside legendary life sciences entrepreneur David Evans
•David Evans is personally investing £1m, no discounted founder shares, TPI clients are invited to invest on the same terms
Turner Pope Investments (TPI) is delighted to introduce a forthcoming AIM IPO: Intuitive Investments Group plc (“IIG”). The principal behind IIG might not, however, need any introduction as David Evans has time and again proven himself an astute stock-picker and operator in the Life Sciences sector for over 25 years. TPI has helped to structure a public vehicle to provide investors access to David’s intuition; the guiding force behind many of his investments to date and the philosophy on which IIG is built. David will be leading the fundraise for IIG with a large personal capital commitment so will have a lot more riding on the Company’s success than reputation alone.
David has been involved in both private and public companies, through investments as well as serving as a senior director of many, including facilitating twelve companies’ transition to being publicly traded, leading many M&A transactions as well as overseeing four successful exits. He was a key member of the team that floated Shield Diagnostics in 1993, later becoming CEO and was responsible for the merger with Axis Biochemicals to create Axis-Shield plc, which was sold in 2011 for £235m. David has served on the board of a number of other quoted Life Sciences companies, including Collagen Solutions plc, Omega Diagnostics Group plc, Genedrive plc, Premaitha Health plc (now Yourgene Health plc), OptiBiotix Health plc, Venn Life Sciences plc (now Open Orphan plc), EKF Diagnostics Holdings plc, Scancell Holdings plc, Immunodiagnostic Systems Holdings plc, BBI Holdings plc (now BBI Diagnostics Group Limited) and Horizon Discovery plc.
At IIG, he will be assisted by experienced non-execs in: Malcolm Gillies, a lawyer by background with a number of director roles with Life Science focused public companies; Cormac Kilty, a founder of a number of Life Science and Diagnostics companies; and Colin Willis, a venture capital specialist with over 24 years of experience in the field including at 3i. In addition, the Board can call upon the knowledge and contacts of an extensive Advisory Panel that includes: Dr. Stewart White, who has acted as Chairman and CEO of numerous Life Science companies; Julian Banes, CEO of EKF Diagnostics; Ron Long, who has held a number of positions as CEO and Chairman of Life Science companies; Per Matsson, who has experience in senior positions in various Life Science R&D departments; and Alistair Smith, CEO of Avacta Group.
We believe the Board and Advisory Panel combined experience will translate to a high level of industry contacts, deal flow and insight to provide investors with a series of opportunities that might otherwise not be available to them in the ordinary course, but which could provide extraordinary returns.
The minimum raise will be £7.5m of which a significant proportion is coming from the Board and associates.
REGISTER YOUR INTEREST BELOW
NOT YET A TPI CLIENT?
We expect this IPO to generate significant interest from our existing clients, however, should you wish to become a TPI client to enable you to partake in the fundraise, please complete all fields in the form to register your interest and we’ll contact you with instructions as to how to open an account.
This is a high risk investment.
ALREADY A TPI CLIENT
If you are an existing client of TPI, please register your interest on the form and a member of the Dealing Team will contact you. Please note, due to the expected level of interest, if you have not been contacted within 24 hours of having received this email, could we kindly request that you call the dealing floor on: (020) 3657 0050.
*Please be aware that there is a minimum subscription of £10,000 and we will not be able to guarantee an allocation, which will be completed on a best endeavours basis. TPI has not considered your ability to afford this investment*
Please be aware that Intuitive Investments Group (IIG) is registered, as opposed to being authorised, with the UK Financial Conduct Authority (FCA) as a Small Registered UK Alternative Investment Fund Manager (AIFM). As such, it must ensure that it remains compliant and operates within the applicable regulatory perimeters, including adhering to the total assets under management (AUM) limit (total of €100mn).
Past performance is not a reliable indicator of future results and future projections may not be achieved.
IIG is a new entrant to the market so its shares do not yet have a liquidity profile. IIG does not have any operating history or historical financial statements with which investors may evaluate it.
Please note, once your positive opt-in has been received, should you decide to withdraw this at any stage, TPI do not consider this in any way detrimental. Should you wish to withdraw your positive opt-in, please email compliance@turnerpope.com with subject line ‘opt-out’ and please ensure that within your email are both your name and email address you wish to opt-out (should this be different to the email address you’ve used to contact us). Additional to the above, you will also be able to click on to the unsubscribe link as included in all TPI emails and update your preferences.
RISK WARNING: The value of shares and the income from them may go down as well as up and you may not get back the money you invested. It should not be assumed that the value of investments will always rise. Past performance is not a reliable indicator of future results and any investment in shares carries the risk that all or some of the capital invested might be lost. Investors should carefully consider their own personal financial circumstances before dealing in the stock market and should seek independent professional advice prior to investing. Investors should ensure that they have the financial capacity to bear the risk and only invest money you can afford to lose.
RISK WARNING – INVESTING IN SMALLER COMPANIES: Companies listed on the AIM market can be highly volatile and are considered high risk speculative investments. You should only consider investing in AIM shares if you have an appropriate degree of equity trading knowledge and experience. It may be difficult to sell the shares on a short-term basis without receiving a significantly lower price than you paid. This is the nature of illiquid investments and their large spread.
Welcome to Turner Pope Investments
Our Mission
Turner Pope Investments is a boutique Stockbroker, providing investment services to Corporate and High Net Worth Private Clients. We strive to ensure that on a day-to-day basis and throughout our organisation, our client’s best interests are always at the very core of our decision-making process. Our mission is to set and maintain an exceptional standard of service to enable us to be regarded as a market leader in our sector by our customers, industry peers and all other associated stakeholders.
Recent Transactions
Corporate Broking
We seek out ambitious, innovative and exciting growth companies whose aspirations match our own and those of our clients, where we are able to build strong, lasting, aligned relationships with management. We look to work with management teams that will listen to our investors and that actively strive to build value for their shareholders.
Engaging our audience
At Turner Pope Investments, we believe it is vitally important for listed companies to engage regularly with their shareholders and as such, we have been organising events since December 2016 at a variety of different venues within the City of London.
Private Clients
Our team of Private Client Stockbrokers is hugely experienced in the management of Private Client portfolios. We pride ourselves on building strong relationships that can stand the test of time, based on our core principles of integrity, trust and placing our clients’ best interests at the very centre of every deal we do.
